



OPEN

Identification of Three Novel Mutations in the *FRMD7* Gene for X-linked Idiopathic Congenital NystagmusXiao Zhang¹, Xianglian Ge¹, Ying Yu², Yilan Zhang¹, Yaming Wu³, Yin Luan⁴, Ji Sun⁵, Jia Qu¹, Zi-Bing Jin¹ & Feng Gu¹

¹School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health and Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou, Zhejiang 325027 China, ²The Community Health Service Center in Huayuan Road, Haidian District, Beijing 10088 China, ³Department of Ophthalmology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000 China, ⁴Department of Ophthalmology, the First Affiliated Hospital of Jilin University, Changchun, Jilin 130021 China, ⁵Department of Pharmacology, University of Washington, Seattle, WA 98195 USA.

Idiopathic congenital nystagmus (ICN) consists of involuntary and periodic ocular motility, often with seriously reduced visual acuity. To identify the genetic defects associated with X-linked ICN, we performed PCR-based DNA direct sequencing of two candidate genes, *FRMD7* and *GPR143*, in four families. Mutation analysis led to identification of three novel mutations, p.S260R, p.Q487X, and p.V549Y fsX554, in *FRMD7* in three of the recruited families. Results from structural modeling indicated that the p.S260R may potentially disrupt *FRMD7* function through loss of a phosphorylation site and/or interference with protein-protein interactions. Both p.Q487X, and p.V549Y fsX554 mutations were predicted to generate nonfunctional truncated proteins. Using a capture next generation sequencing method, we excluded *CASK* as the responsible gene for the remaining family. Combining sequence analysis and structural modeling, we report three novel mutations in *FRMD7* in three independent families with XLICN, and provide molecular insights for future XLICN diagnosis and treatment.

Idiopathic congenital nystagmus (ICN) causes involuntary and periodic ocular motility, and often seriously reduces visual acuity. It is the most common oculomotor disorder characterized by bilateral uncontrollable ocular oscillation¹, which usually presents in infancy or within the first few months after birth without any other sensory defect². However, the inheritance pattern is heterogeneous, with autosomal dominant, autosomal recessive, or X-linked (XLICN) patterns, among which X-linked is the most common^{3,4}. Genes causing XLICN have been mapped at three loci (Xp11.4–p11.3, Xp22, and Xq26–q27)^{1,5,6}. XLICN, mapped to Xq26–q27, is linked to the *FRMD7* gene⁷, which encodes a member of the protein 4.1 superfamily⁷. *GPR143* resides at Xp22 and mutations within it are primarily linked to ocular albinism (OA), where nystagmus results as a secondary phenotype. However, *GPR143* mutations have been reported in XLICN families, without the classical phenotype of ocular albinism^{8–10}. Recently, Watkins et al. reported mutations in the *CASK* gene, locates at Xp11.4–p11.3, is linked with XLICN and mental retardation¹¹. Taken together, so far, two genes (*FRMD7* and *GPR143*) have been identified as causative genes for XLICN and *CASK* for XLICN with mental retardation, respectively.

Here, we recruited four families diagnosed with XLICN. Through direct sequencing for the two candidate genes, *FRMD7* and *GPR143*, we identified three novel mutations in *FRMD7* in three independent families. Meanwhile, we have excluded *CASK*, *FRMD7*, and *GPR143* as the disease gene for the remaining family, which provides more evidence to show the genetic heterogeneity associated with XLICN and paves the way for discovering new disease genes for XLICN.

Results

Clinical data. The patterns of inheritance of these four families are X-linked as indicated by the pedigrees (Figure 1). The clinical data are summarized in Table 1. Mental retardation, night blindness, and photophobia are not observed in any of the affected individuals in any family, nor is there any incidence of systemic or other ocular anomalies.

SUBJECT AREAS:

NEUROMUSCULAR
DISEASE

GENETIC TESTING

MOLECULAR MODELLING

DNA SEQUENCING

Received

21 October 2013

Accepted

23 December 2013


Published

17 January 2014


Correspondence and requests for materials should be addressed to F.G. (fgu@mail.eye.ac.cn)




Family A



Family B



Family C



Family D




Figure 1 | Pedigrees of four families with X-linked congenital nystagmus. Squares indicate males, circles indicate females, and slashed symbols indicate deceased, black symbols indicate affected individuals, unfilled symbols indicate unaffected individuals, and unaffected, obligate carriers are represented by a dotted circle. Arrow marks the proband.

Mutation identification and analysis. In family A (Figure 1), a novel missense mutation, c.780C > A, was identified at codon 780 (AGC to AGA) in exon 9 of *FRMD7* gene. The c.780C > A mutation causes a substitution of serine to arginine at position 260 (p.S260R) of the *FRMD7* protein (Figure 2). The p.S260R mutation occurred at a residue that is evolutionarily highly conserved (Figure 3). Results from online software prediction program strongly suggest that p.S260R variation is a pathogenic mutation. In family B, a nonsense mutation Q487X in exon 12 of *FRMD7* introduces a premature stop codon and produces a truncated protein, which is missing the C-terminal 228 residues (Figure 2, 3). In family C, the deletion mutation (c.1645del G) in exon 12 of *FRMD7*, which is predicted to cause a frame shift at codon 549 and will stop the open reading frame at codon 554, thereby generating a prematurely truncated *FRMD7* protein (Figure 2, 3).

These mutations cosegregated with affected individuals or carriers in the family (A, B, C), and were not present in any of the unaffected family members (A, B, C) or 200 normal controls. The rest of the coding regions did not show any sequence changes.

We searched these mutations in multiple databases, including the dbSNPs (v130), HapMap, 1000 Genome, and 702 in-house exome data. The candidate mutations were not present in these databases. No mutation in *FRMD7* was identified in family D and no mutations in *GPR143* were detected in any individual among the four families.

We first manually checked of sequencing depth of *CASK* gene. On average, a mean coverage of 88X over the exons in this gene was achieved (Table S1). We further scanned the mutations in *CASK* gene, and no mutations were identified (Table S1).

Table 1 | Clinical findings of individuals in this study

Family	Individual ID	Age (Y)	Age at onset	Best corrected visual acuity at presentation	Clinical findings
Family A	III:5	35	Early Infancy	20/50	Head nodding (+), -4.00
	III:7	24	Early Infancy	20/33	Head nodding (+), -3.00
	IV:3	13	Early Infancy	20/50	Head nodding(+), -3.00
Family B	III:4	22	Early Infancy	20/80	Head nodding (+), -5.50/0.5 × 90
Family C	III:1	27	Early Infancy	20/40	Head nodding (+), -6.00/2 × 90
Family D	III:9	24	Early Infancy	20/40	Head nodding (+), -1.00/3 × 90
	IV:1	25	Early Infancy	20/40	Head nodding (+), -4.00




Figure 2 | Sequencing results of affected males and controls. Three mutations of *FRMD7* were identified in three families, which were c.780 C > A (p.S260R) in family (A), c.1458 C > T (p.Q487X) in family (B), one G deletion mutation in family (C).




Figure 3 | Multiple-sequence alignment of *FRMD7* protein from different species. The red outline in the alignment shows the amino acid affected by the mutation. The deletion mutation (bottom C), which leads to a frameshift mutation, the amino acid residues in red are the residues after frameshift mutation.

Taking this evidence together, we conclude that p.S260R, p.Q487X and p.V549YfsX554 are causative mutations in *FRMD7*, rather than benign polymorphisms in linkage disequilibrium with *XLICN*.

Discussion

ICN is the most common inherited eye disease manifesting with nystagmus, and patients with this disease usually have problems with visual acuity. Here we recruited four families with *XLICN*, with the




Figure 4 | Structural model of the *FRMD7* protein. (A) The 3D model of *FRMD7* (1–336) with the key mutation S260 colored in orange. (B) View of *FRMD7* after 90 degree rotation. (C) The surface representation of B and the surface is color according to the conservation of the primary sequence. Green regions are strictly conserved, regions in purple are the least conserved areas, and anything in-between is colored white. S260 locates on a large conserved surface.

Table 2 | *FRMD7/GPR143* mutations and best corrected visual acuity(BCVA)

Gene	Mutation	BCVA	Ref.
<i>FRMD7</i>	c.163-1 G > T	20/60–20/25	Hu, Y, 2012
<i>FRMD7</i>	c.673T > G, p.W225G	20/100–20/22	Schorderet DF, 2007
<i>FRMD7</i>	c.780C > A, p.S260R	20/50–20/33	In this study
<i>FRMD7</i>	c.1458G > T, p.Q487X	20/80	In this study
<i>FRMD7</i>	c.1645del G, p.V549YfsX554	20/40	In this study
<i>GPR143</i>	c.658 + 1 G > T	20/200–20/100	Hu J, 2011
<i>GPR143</i>	c.807T > A, p.Y269X	20/2000–20/100	Yan N, 2012
<i>GPR143</i>	c.816del 14 bp	20/200–20/170	Preising M, 2001

goal of identifying the genetic defects present in these families. Since only *FRMD7* and *GPR143* have been reported as causative genes for XLICN, we focused our attention on these two candidates. After comprehensive screening for mutations by direct sequencing, three novel mutations in *FRMD7* were identified but no mutation was identified in *GPR143*. This study thus provides further evidence to show the role of *FRMD7* in the pathogenesis of XLICN, which is consistent with previous evidence that 47% of the XLICN pedigrees in the Chinese population have yielded *FRMD7* mutations¹². Family D was also recruited but no *FRMD7* or *GPR143* mutations were identified in these individuals. Recently, there was a report that showed *CASK* may be one of the responsible genes for XLICN with mental retardation; we excluded it in the families of this study by capture next generation sequencing. These results further highlight the genetically heterogeneous nature of ICN, since at least four loci have been proposed for familial ICN. It also illustrates the unique role of *FRMD7* in XLICN.

The *FRMD7* protein (ENSP00000298542) consists of an N-terminal FERM domain, a FERM adjacent domain and a region without any significant homology to other proteins. The FERM domain is located between amino acids 2–282, and the FERM-C (F3) domain is located at residues 186–279 in *FRMD7*. Using the Phyre2¹³ program, we predicted the secondary structure of the wild-type *FRMD7* protein. We modeled the 3D structure of the wild type *FRMD7* protein (1–336), and mapped out the S260 in the structure (Figure 4). The p.S260R mutation localizes to the FERM-C domain, and introduces a larger amino acid (arginine) into a restricted area¹⁴. Since the S260 residue is solvent exposed, we rationalize that the point mutation (p.S260R) may potentially disrupt *FRMD7* function through one of the following mechanisms. Firstly, S260 is predicted to be a phosphorylation site, and p.S260R mutation will surely prevent the phosphorylation event, and thus alter the regulation of *FRMD7*¹⁵. Secondly, we mapped out the conserved regions of the *FRMD7* surface. S260 is located in an extremely conserved surface that usually is involved in protein-protein interactions. It would not be surprising if any point mutation on this surface interferes with the interaction with other proteins, and therefore contribute to the pathogenesis of the disease.

The nonsense mutation and the deletion mutation in *FRMD7* were predicted to cause gross defects at the protein level and loss of the

protein function. To date, five mutations^{14,16–18} have been reported in exon 12 of *FRMD7*, all of which are predicted to produce truncated proteins. In the present study, two novel mutations in exon 12 were identified. Both are predicted to lead to premature termination of translation. It highlighted that the C-terminal region, which is a highly conserved domain, plays a critical role in the function of *FRMD7* protein¹¹.

The association between best corrected visual acuity (BCVA) and the type of XLICN mutations is of interest, since it may help the clinical genetic diagnosis. Since mutations in *FRMD7* or *GPR143* both can cause XLICN, we reviewed the literature to collect the available data of these two genes mutations and BCVA data, which was summarized in Table 2. We observed that patients with mutations in *GPR143* have worse BCVA^{19–21}, compared to those with mutations in *FRMD7*^{2,22}. Study data is consistent with the reported literature indicating a better BCVA in *FRMD7* compared to *GPR143* patients.

In summary, our findings have further expanded the mutational spectrum of *FRMD7* and further confirmed the genetic heterogeneity of XLICN. By structural modeling, we predicted the consequence of the p.S260R mutation.

Meanwhile, from limited available data, it is suggested that XLICN patients with lower BCVA may have *GPR143* gene mutations. However, the specific molecular consequence of these mutations in *FRMD7* is not clear. Further studies are needed to provide insights into the detailed molecular pathogenesis of the mutations identified in the present study.

Methods

Clinical evaluations and DNA specimens. This study conformed to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Eye Hospital, Wenzhou Medical University. Written informed consent was obtained from all participating individuals or their guardians. Patients from four families (A, B, C and D, Figure 1) originating from the provinces of Helongjiang, Jilin, Inner Mongol and Shandong, respectively, were recruited. Clinical and ophthalmological examinations were performed by ophthalmologists.

Mutation analysis. Primers were designed to cover the sequences of all coding exons and splice junctions of *FRMD7* and *GPR143*. The DNA sequences of *FRMD7* and *GPR143* were obtained from the GenBank database (NM_194277.1 and NM_000273.2). The primer sequences of *FRMD7* have been published²³, and the primers and amplification conditions for *GPR143* are listed in Table 3.

Table 3 | Primers and PCR Conditions for *GPR143* gene

Exon	Primer F (5'-3')	Primer R (5'-3')	Annealing temp.	Length (bp)
1	GGCCGGCGGGTCTCGGCACA	CAGGTCAAATCCACAGGCC	60°C	360
2	TCCCTCCTTCCTTCCTTCCTCT	CCCATGTAAGCGGAGGATGCATT	62°C	478
3	TCCCTGCATACAAGTGGAGCAGAA	ACAAGCCACTGTGCCTGGCTAATA	62°C	544
4	AAACAACCAACCAACCTCAGCAGC	TGATTCCAGGGTCACTTCTCCAAGC	58°C	452
5	CTTTGGGCAGTCAGCAGCAGATT	TCCTGGCACTGAGCTAACAAACGA	58°C	480
6	TCAGTGACTTGCTTGCTTCCTGC	CAGCAATGCACATGGTTGGGACAT	58°C	530
7	AAAGTGCTGGGATTACAGGAGGGA	AGGCCAAGACAGAGGATTGCTTGA	68°C	436
8	TTTCAGGCACCTTGAAGGTACAG	GTGCAACTGGAAGCTAGTGAGT	58°C	612
9	TGCAGATGAGATGAATGCTAGGAC	AGTGTGCTGTAGCCTGTACCATCT	58°C	750



PCR products were sequenced on an ABI PRISM 3730 DNA Sequencer (Applied Biosystems, Foster City, CA). Sequences were aligned and the mutations were detected using Mutation Surveyor software (Soft Genetics, USA, www.softgenetics.com). The effects of the mutations on the protein coding region (synonymous, missense, nonsense, frameshift, etc) were predicted by Exome-assistant²². The effects of the mutations on protein function were assessed by four online softwares, including Polyphen2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT (<http://sift.jcvi.org/>), Pmut (<http://mmb2.pcb.ub.es:8080/PMut/>) and Panther (<http://www.pantherdb.org/tools/csnpscoreForm.jsp>).

A total of 7080 exons on the X chromosome (Table S2) were selected by a gene capture strategy using the GenCap custom enrichment kit (MyGenostics, Beijing), which has been previously described²³. The enrichment libraries were sequenced on an Illumina Solexa HiSeq 2000 sequencer for paired read 100 bp. The analysis was described previously²³. Briefly, using the Solexa QA the cutadapt (<http://code.google.com/p/cutadapt/>), SOAP aligner, BWA and GATK programs to retrieve and align to identify SNPs and insertions or deletions (InDels). SNPs and InDels were annotated using the exome-assistant program (<http://122.228.158.106/exomeassistant>). We selected the CASK gene (NM_001126054) for the mutation survey.

1. Cabot, A. *et al.* A gene for X-linked idiopathic congenital nystagmus (NYS1) maps to chromosome Xp11.4–p11.3. *Am J Hum Genet.* **64**, 1141–1146 (1999).
2. Hu, Y. *et al.* A novel splicing mutation of the FRMD7 gene in a Chinese family with X-linked congenital nystagmus. *Mol Vis* **18**, 87–91 (2012).
3. Self, J. & Lotery, A. The molecular genetics of congenital idiopathic nystagmus. *Semin Ophthalmol.* **21**, 87–90 (2006).
4. Thomas, S. *et al.* Phenotypical characteristics of idiopathic infantile nystagmus with and without mutations in FRMD7. *Brain.* **131**, 1259–1267 (2008).
5. Bassi, M. T. *et al.* Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. *Nat Genet.* **10**, 13–19 (1995).
6. Kerrison, J. B. *et al.* Congenital motor nystagmus linked to Xq26–q27. *Am J Hum Genet.* **64**, 600–607 (1999).
7. Chishti, A. H. *et al.* The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. *Trends Biochem Sci.* **23**, 281–282 (1998).
8. Watkins, R. J. *et al.* The Role of FRMD7 in Idiopathic Infantile Nystagmus. *J Ophthalmol.* **2012**, 460956 (2012).
9. Zhou, P. *et al.* Identification of a novel GPR143 deletion in a Chinese family with X-linked congenital nystagmus. *Mol Vis.* **14**, 1015–1019 (2008).
10. Liu, J. Y. *et al.* Identification of a novel GPR143 mutation in a large Chinese family with congenital nystagmus as the most prominent and consistent manifestation. *J Hum Genet.* **52**, 565–570 (2007).
11. Watkins, R. J. *et al.* A novel interaction between FRMD7 and CASK: evidence for a causal role in idiopathic infantile nystagmus. *Hum Mol Genet.* **22**, 2105–2118 (2013).
12. He, X. *et al.* A novel frameshift mutation in FRMD7 causing X-linked idiopathic congenital nystagmus. *Genet Test.* **12**, 607–613 (2008).
13. Kelley, L. A. & Sternberg, M. J. E. Protein structure prediction on the Web: a case study using the Phyre server. *Nat Protoc.* **4**, 363–371 (2009).
14. Tarpey, P. *et al.* Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. *Nat Genet.* **38**, 1242–1244 (2006).

15. Tsukita, S. & Yonemura, S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. *J Biol Chem.* **274**, 34507–34510 (1999).
16. Khan, A. O. *et al.* Prolonged Pursuit by Optokinetic Drum Testing in Asymptomatic Female Carriers of Novel FRMD7 Splice Mutation c. 1050 + 5 G > A. *Arch Ophthalmol-Chic.* **129**, 936–940 (2011).
17. He, X. *et al.* A Novel Frameshift Mutation in FRMD7 Causing X-Linked Idiopathic Congenital Nystagmus. *Genet Test.* **12**, 607–613 (2008).
18. Du, W. *et al.* A novel frame-shift mutation in FRMD7 causes X-linked idiopathic congenital nystagmus in a Chinese family. *Mol Vis.* **17**, 2765–2768 (2011).
19. Hu, J. *et al.* A novel GPR143 splicing mutation in a Chinese family with X-linked congenital nystagmus. *Mol Vis.* **17**, 715–722 (2011).
20. Yan, N. *et al.* A novel nonsense mutation of the GPR143 gene identified in a Chinese pedigree with ocular albinism. *PLoS One.* **7**, e43177 (2012).
21. Preising, M. *et al.* Deletion in the OA1 gene in a family with congenital X linked nystagmus. *Br J Ophthalmol.* **85**, 1098–1103 (2001).
22. Schorderet, D. F. *et al.* Novel mutations in FRMD7 in X-linked congenital nystagmus. Mutation in brief #963. Online. *Hum Mutat.* **28**, 525 (2007).
23. Huang, X. F. *et al.* Targeted exome sequencing identified novel USH2A mutations in Usher syndrome families. *PLoS One.* **8**, e63832 (2013).

Acknowledgments

We thank the families for their participation in this project. We are indebted to Dr. Jinyu Wu (Institute of Genomic Medicine, Wenzhou Medical University) for bioinformatics analysis. This work was supported by grants from the Chinese National Program on Key Basic Research Project (973 Program, 2013CB967502, F.G.), the Natural Science Foundation of China (81201181/H1818, F.G.), Zhejiang provincial & Ministry of Health research fund for medical sciences (WKJ2013-2-023, F.G.), Wenzhou Medical College PI starting grant (QJT12011, F.G.).

Author contributions

F.G. and J.Q. conceived the idea, X.Z., X.L.G., Y.Y., Y.L.Z., Y.M.W. and Y.L. collected the samples and performed the experiments, Z.B.J. and F.G. performed data analyses, X.Z. and J.S. performed structural modeling. F.G. wrote the manuscript. All authors have read and approved the final manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, X. *et al.* Identification of Three Novel Mutations in the FRMD7 Gene for X-linked Idiopathic Congenital Nystagmus. *Sci. Rep.* **4**, 3745; DOI:10.1038/srep03745 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>